Your session is about to expire
← Back to Search
Fluorescent Imaging for Premalignant Oral Lesions
N/A
Waitlist Available
Led By Ann M Gillenwater
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients with a history of head and neck cancer or oral premalignant disease but without any clinical evidence of disease
Subjects with premalignant lesion, or potentially premalignant lesion, of the oral cavity mucosa (leukoplakia or erythroplakia)
Must not have
Subjects under the age of 18
Subjects that are unable or unwilling to give informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is examining if using fluorescent imaging, spectroscopy, and tissue samples can help detect oral cancer earlier.
Who is the study for?
This trial is for adults at high risk of developing oral cancer, including those with conditions like lichen planus, Fanconi anemia, heavy tobacco use, or premalignant lesions in the mouth. It's also open to patients with a history of head and neck cancer but currently show no signs of disease.
What is being tested?
The study tests imaging techniques that detect light emitted from tissues (fluorescence) to monitor for early signs of oral cancer. This includes taking pictures inside the mouth using special lights and cameras, as well as examining tissue samples under a microscope.
What are the potential side effects?
Since this trial involves diagnostic procedures rather than drug treatments, side effects are minimal but may include discomfort from the imaging equipment or during sample collection.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I had head or neck cancer or precancerous oral conditions but currently show no signs of disease.
Select...
I have a precancerous lesion in my mouth.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am under 18 years old.
Select...
I am unable or unwilling to give informed consent.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 10 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Lesions diagnosed via non-invasive brush cytology
Lesions diagnosed via point spectroscopy system
Lesions diagnosed via wide-field fluorescence imaging
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (fluorescent/reflectance imaging, spectroscopy)Experimental Treatment5 Interventions
Participants' oral cavities are inspected by a clinician using a standard white light headlamp. Participants then undergo oral mucosa examination using wide-field reflectance and fluorescence imaging, and/or fluorescence spectroscopy imaging. Standard oral brush biopsies are also performed and examined microscopically. Participants may undergo repeated imaging procedures and biopsy during subsequent follow up visits.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Diagnostic Microscopy
2017
Completed Early Phase 1
~100
Fluorescence Spectroscopy
1999
N/A
~390
Fluorescence Imaging
2014
Completed Phase 2
~100
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for oral tumors include surgery, radiation therapy, and chemotherapy. Surgery involves the physical removal of the tumor, which is often the first line of treatment.
Radiation therapy uses high-energy rays to target and kill cancer cells, while chemotherapy employs drugs to destroy cancer cells throughout the body. Fluorescence and reflectance imaging, along with fluorescence spectroscopy, are advanced diagnostic techniques that help detect abnormal cells by using light-induced fluorescence.
These methods are crucial for early detection, allowing for timely and more effective treatment, which can significantly improve outcomes for oral tumor patients.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,066 Previous Clinical Trials
1,801,907 Total Patients Enrolled
10 Trials studying Tobacco Use Disorder
4,107 Patients Enrolled for Tobacco Use Disorder
National Cancer Institute (NCI)NIH
13,924 Previous Clinical Trials
41,017,613 Total Patients Enrolled
97 Trials studying Tobacco Use Disorder
1,683,069 Patients Enrolled for Tobacco Use Disorder
Ann M GillenwaterPrincipal InvestigatorM.D. Anderson Cancer Center
Share this study with friends
Copy Link
Messenger